Skip to main content
  • Saved

made a Post

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy

Source :

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481581/

Wenfeng Fang, 1, # Yihua Huang, 1, # Weiguang Gu, 2, 3, # Jiadi Gan, 1 Wenjing Wang, 4 Shiyue Zhang, 4 Kai Wang, 4 Jianhua Zhan, 1 Yunpeng Yang, 1 Yan Huang, 1 Hongyun Zhao, 1 and Li Zhang 1 Several mechanisms including abnormal activation of PI3K-AKT-mTOR pathway have been proved to generate acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).